Literature DB >> 28149576

Duration of antibiotic therapy in the intensive care unit.

Gabor Zilahi1, Mary Aisling McMahon1, Pedro Povoa2, Ignacio Martin-Loeches3.   

Abstract

There are certain well defined clinical situations where prolonged therapy is beneficial, but prolonged duration of antibiotic therapy is associated with increased resistance, medicalising effects, high costs and adverse drug reactions. The best way to decrease antibiotic duration is both to stop antibiotics when not needed (sterile invasive cultures with clinical improvement), not to start antibiotics when not indicated (treating colonization) and keep the antibiotic course as short as possible. The optimal duration of antimicrobial treatment for ventilator-associated pneumonia (VAP) is unknown, however, there is a growing evidence that reduction in the length of antibiotic courses to 7-8 days can minimize the consequences of antibiotic overuse in critical care, including antibiotic resistance, adverse effects, collateral damage and costs. Biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) do have a valuable role in helping guide antibiotic duration but should be interpreted cautiously in the context of the clinical situation. On the other hand, microbiological criteria alone are not reliable and should not be used to justify a prolonged antibiotic course, as clinical cure does not equate to microbiological eradication. We do not recommend a 'one size fits all' approach and in some clinical situations, including infection with non-fermenting Gram-negative bacilli (NF-GNB) clinical evaluation is needed but shortening the antibiotic course is an effective and safe way to decrease inappropriate antibiotic exposure.

Entities:  

Keywords:  Multidrug resistant (MDR); de-escalation; intensive care unit (ICU); sepsis; stewardship; ventilator-associated pneumonia (VAP)

Year:  2016        PMID: 28149576      PMCID: PMC5227227          DOI: 10.21037/jtd.2016.12.89

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  32 in total

Review 1.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.

Authors:  Benjamin M P Tang; Guy D Eslick; Jonathan C Craig; Anthony S McLean
Journal:  Lancet Infect Dis       Date:  2007-03       Impact factor: 25.071

2.  Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration.

Authors:  Erika M C D'Agata; Pierre Magal; Damien Olivier; Shigui Ruan; Glenn F Webb
Journal:  J Theor Biol       Date:  2007-08-25       Impact factor: 2.691

3.  Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection?

Authors:  J Rello; D Mariscal; F March; P Jubert; F Sanchez; J Valles; P Coll
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

4.  Procalcitonin increase in early identification of critically ill patients at high risk of mortality.

Authors:  Jens Ulrik Jensen; Lars Heslet; Tom Hartvig Jensen; Kurt Espersen; Peter Steffensen; Michael Tvede
Journal:  Crit Care Med       Date:  2006-10       Impact factor: 7.598

Review 5.  Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.

Authors:  Philipp Schuetz; Beat Müller; Mirjam Christ-Crain; Daiana Stolz; Michael Tamm; Lila Bouadma; Charles E Luyt; Michel Wolff; Jean Chastre; Florence Tubach; Kristina B Kristoffersen; Olaf Burkhardt; Tobias Welte; Stefan Schroeder; Vandack Nobre; Long Wei; Neera Bhatnagar; Heiner C Bucher; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

6.  Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial.

Authors:  Carolina F Oliveira; Fernando A Botoni; Clara R A Oliveira; Camila B Silva; Helena A Pereira; José C Serufo; Vandack Nobre
Journal:  Crit Care Med       Date:  2013-10       Impact factor: 7.598

7.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

8.  A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.

Authors:  Marin H Kollef; Jean Chastre; Marc Clavel; Marcos I Restrepo; Bart Michiels; Koné Kaniga; Iolanda Cirillo; Holly Kimko; Rebecca Redman
Journal:  Crit Care       Date:  2012-11-13       Impact factor: 9.097

Review 9.  What's new in multidrug-resistant pathogens in the ICU?

Authors:  Gabor Zilahi; Antonio Artigas; Ignacio Martin-Loeches
Journal:  Ann Intensive Care       Date:  2016-10-06       Impact factor: 6.925

10.  Predicting treatment failure in patients with community acquired pneumonia: a case-control study.

Authors:  Ignacio Martin-Loeches; Xavier Valles; Rosario Menendez; Oriol Sibila; Beatriz Montull; Catia Cilloniz; Antonio Artigas; Antoni Torres
Journal:  Respir Res       Date:  2014-07-05
View more
  16 in total

1.  Why Antibiotic Treatment Is Not Enough for Sepsis Resolution: an Evaluation in an Experimental Animal Model.

Authors:  Jonathan L Halbach; Andrew W Wang; Dennis Hawisher; David M Cauvi; Radhames E Lizardo; Joseph Rosas; Tony Reyes; Omar Escobedo; Stephen W Bickler; Raul Coimbra; Antonio De Maio
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

Review 2.  Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies.

Authors:  David Nora; Pedro Póvoa
Journal:  Ann Transl Med       Date:  2017-11

Review 3.  Role of procalcitonin use in the management of sepsis.

Authors:  Claudia Gregoriano; Eva Heilmann; Alexandra Molitor; Philipp Schuetz
Journal:  J Thorac Dis       Date:  2020-02       Impact factor: 2.895

4.  Predictive modeling of bacterial infections and antibiotic therapy needs in critically ill adults.

Authors:  Garrett Eickelberg; L Nelson Sanchez-Pinto; Yuan Luo
Journal:  J Biomed Inform       Date:  2020-08-16       Impact factor: 6.317

5.  Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis.

Authors:  Kimberly C Claeys; Evan J Zasowski; Trang D Trinh; Abdalhamid M Lagnf; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2017-11-21

6.  Feasibility of Antimicrobial Stewardship (AMS) in Critical Care Settings: A Multidisciplinary Approach Strategy.

Authors:  Tamas Tiszai-Szucs; Claire Mac Sweeney; Joseph Keaveny; Fernando A Bozza; Zieta O Hagan; Ignacio Martin-Loeches
Journal:  Med Sci (Basel)       Date:  2018-05-25

Review 7.  Host-pathogen interaction during mechanical ventilation: systemic or compartmentalized response?

Authors:  Sean Keane; Ignacio Martin-Loeches
Journal:  Crit Care       Date:  2019-06-14       Impact factor: 9.097

8.  Machine Learning Techniques to Identify Antimicrobial Resistance in the Intensive Care Unit.

Authors:  Sergio Martínez-Agüero; Inmaculada Mora-Jiménez; Jon Lérida-García; Joaquín Álvarez-Rodríguez; Cristina Soguero-Ruiz
Journal:  Entropy (Basel)       Date:  2019-06-18       Impact factor: 2.524

9.  Time to positivity of blood cultures supports early re-evaluation of empiric broad-spectrum antimicrobial therapy.

Authors:  Merel M C Lambregts; Alexandra T Bernards; Martha T van der Beek; Leo G Visser; Mark G de Boer
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

Review 10.  Optimizing the Use of Antibiotic Agents in the Pediatric Intensive Care Unit: A Narrative Review.

Authors:  Jef Willems; Eline Hermans; Petra Schelstraete; Pieter Depuydt; Pieter De Cock
Journal:  Paediatr Drugs       Date:  2020-11-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.